BERLIN, Oct. 8, 2007 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) announced today that the complete New Drug Application (NDA) for Icatibant in the treatment of hereditary angioedema (HAE) has been sent to the US Food and Drug Administration (FDA) via an Electronic Common Technical Document (eCTD) for technical testing. After receiving technical clearance of the eCTD from the FDA, the regulatory review period will begin.
